Genetic map offers new tool for malaria research
Scientists create genome-scale map of genetic variation for malaria parasite; initial use unlocks genes involved in drug resistance
Boston, MA and Cambridge, MA, Sun. December 10, 2006 -- An international research team announced today the completion of a genome-wide map that charts the genetic variability of the human malaria parasite Plasmodium falciparum. Published in the December 10 advance online edition of Nature Genetics, the study reveals striking variation within the pathogen's genome, including an initial catalog of nearly 47,000 specific genetic differences among parasites sampled worldwide. These differences lay the foundation for dissecting the functions of important parasite genes and for tracing the global spread of malaria. Led by scientists at the Harvard School of Public Health and the Broad Institute of MIT and Harvard, together with researchers in Senegal, the work has already unearthed novel genes that may underlie resistance to current drugs against the disease.
"Malaria remains a significant threat to global public health, driven in part by the genetic changes in the parasite that causes the disease," said senior author Dyann Wirth, a professor and chairman of the department of immunology and infectious diseases at the Harvard School of Public Health and the co-director of the Broad Institute's Infectious Disease Initiative. "This study gives us one of the first looks at genetic variation across the entire malaria parasite genome — a critical step toward a comprehensive genetic tool for the malaria research community."
Plasmodium falciparum — the deadliest of the four parasites that cause malaria in humans — kills one person every 30 seconds, mostly children living in Africa. Despite decades of research, the genetic changes that enable it to escape the body's natural defenses and to overcome malaria drugs remain largely unknown.
To gain a broad picture of genetic variability — worldwide and genome-wide — the scientists analyzed more than 50 different P. falciparum samples from diverse geographic locations. This includes the complete genome sequencing of two well-studied samples as well as extensive DNA analyses of 16 additional isolates. The work is one of three large-scale studies of the parasite's DNA that appear together in Nature Genetics, and it represents a collaborative effort among Boston area researchers and a scientific team led by Souleymane Mboup, a professor at the Cheikh Anta Diop University in Senegal where malaria is endemic. "We are grateful for the contributions of our colleagues in Senegal. They are a crucial part of this collaboration," said Wirth.
By comparing the DNA sequences to each other and to the P. falciparum genome sequenced in 2002, the researchers uncovered extensive differences, including ~ 47,000 single letter changes called single nucleotide polymorphisms (SNPs). This represents more than double the expected level of diversity in the parasite's DNA. Although there are probably many more SNPs to be found, this initial survey — like the recent HapMap project in humans — provides a launching point for future systematic efforts to identify parasite genes that are essential to malaria.
"The roles of most of the malaria parasite's genes are still not known," said first author Sarah Volkman, a research scientist at the Harvard School of Public Health. "An important application of this new tool will be in pinpointing the genes that are vital to the development and spread of malaria."
One of the tool's strengths is its ability to reveal evolutionary differences among parasites. This information can shed light on the genes responsible for malaria drug resistance — a major obstacle to adequate control of the disease. Using the genetic map to compare parasites exposed to different anti-malarial drugs, the scientists identified a novel region that is strongly implicated in resistance to the drug pyrimethamine, and also confirmed a region of the genome known to be involved in chloroquine drug resistance.
"The same genetic principles used to study human evolution can provide important clues about malaria," said first author Pardis Sabeti, a postdoctoral fellow at the Broad Institute. "This tool has already yielded insights into the genetic changes that correlate with different drug treatments, pointing us to genes that may contribute to drug resistance."
The map can also define the genetic landscapes of different parasite populations. Applying it to parasites from various continents, the scientists discovered greater DNA variability among P. falciparum samples from Africa relative to those from Asia and the Americas. This knowledge guides the selection of genetic markers to track the transmission of distinct parasites, particularly ones that are virulent or drug resistant. It also lays the groundwork for connecting parasite genes with traits that vary geographically and bolster malaria's foothold in many parts of the world.
"Genomic tools have largely been applied to first-world diseases up to now. This project underscores the power and importance of applying them to the devastating diseases of the developing world," said Eric Lander, one of the study's authors and the director of the Broad Institute. "By joining forces among scientists in the U.S., Africa and elsewhere, it should be possible to rapidly reveal the genetic variation in malaria around the world. Knowing the enemy will be a crucial step in fighting it."
Funding and data access
This work was supported by several funding organizations, including the Bill and Melinda Gates Foundation, the Burroughs-Wellcome Fund, the Exxon Mobil Foundation, the National Institutes of Allergy and Infectious Disease Microbial Sequencing Center, and the National Institutes of Health.
Volkman et al., (2006) A genome-wide map of diversity in Plasmodium falciparum; Nature Genetics; DOI:10.1038/ng1930
A complete list of the study's authors and their affiliations:
Sarah K. Volkman1*, Pardis C. Sabeti2*, David DeCaprio2, Daniel E. Neafsey2, Stephen F. Schaffner2, Danny A. Milner, Jr.1, Johanna P. Daily1, Ousmane Sarr3, Daouda Ndiaye3, Omar Ndir3, Souleymane Mboup3, Manoj T. Duraisingh1, Amanda Lukens1, Alan Derr2, Nicole Stange-Thomann2, Skye Waggoner2, Robert Onofrio2, Liuda Ziaugra2, Evan Mauceli2, Sante Gnerre2, David B. Jaffe2, Joanne Zainoun2, Roger C. Wiegand2, Bruce W. Birren2, Daniel L. Hartl4, James E. Galagan2, Eric S. Lander2, 5, 6, 7, Dyann F. Wirth1,2.
*These authors contributed equally to this work.
1Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA.
2The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA,
3Faculty of Medicine and Pharmacy, Cheikh Anta Diop University, Dakar, Senegal
4Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA.
5Department of Biology, MIT, Cambridge, MA USA.
6Whitehead Institute for Biomedical Research, Cambridge, MA, USA.
7Department of Systems Biology, Harvard Medical School, Boston, MA, USA.
About the Harvard School of Public Health
Harvard School of Public Health is dedicated to advancing the public's health through learning, discovery, and communication. More than 300 faculty members are engaged in teaching and training the 900-plus student body in a broad spectrum of disciplines crucial to the health and well being of individuals and populations around the world. Programs and projects range from the molecular biology of AIDS vaccines to the epidemiology of cancer; from risk analysis to violence prevention; from maternal and children's health to quality of care measurement; from health care management to international health and human rights. For more information visit http://www.hsph.harvard.edu
About the Broad Institute of MIT and Harvard
The Broad Institute of MIT and Harvard was founded in 2003 to bring the power of genomics to biomedicine. It pursues this mission by empowering creative scientists to construct new and robust tools for genomic medicine, to make them accessible to the global scientific community, and to apply them to the understanding and treatment of disease.
The Institute is a research collaboration that involves faculty, professional staff and students from throughout the MIT and Harvard academic and medical communities. It is jointly governed by the two universities.
Organized around Scientific Programs and Scientific Platforms, the unique structure of the Broad Institute enables scientists to collaborate on transformative projects across many scientific and medical disciplines.
For further information about the Broad Institute, go to http://www.broad.mit.edu.
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.